Antiganglioside antibodies and their pathophysiological effects on Guillain-Barré syndrome and related disorders - A review

Glycobiology

Volumn 19, Issue 7, 2009, Pages 676-692

  Kaida, Kenichi ^a   Ariga, Toshio ^a   Yu, Robert K ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Bacterial infection; Guillain Barr syndrome; Inflammation; Llipopolysaccharides; Molecular mimicry; Peripheral neuropathy

Indexed keywords

ACETYLGALACTOSAMINYLTRANSFERASE GANGLIOSIDE GD 1A ANTIBODY; ANTIBODY; APT 070; BACTERIUM LIPOPOLYSACCHARIDE; COMPLEMENT INHIBITOR; ECULIZUMAB; GANGLIOSIDE; GANGLIOSIDE ANTIBODY; GANGLIOSIDE COMPLEX; GANGLIOSIDE GD 1A; GANGLIOSIDE GD 1A ANTIBODY; GANGLIOSIDE GD 1B; GANGLIOSIDE GD 1B ANTIBODY; GANGLIOSIDE GD3 ANTIBODY; GANGLIOSIDE GM1; GANGLIOSIDE GM1 ANTIBODY; GANGLIOSIDE GQ 1B ANTIBODY; MIROCOCEPT; UNCLASSIFIED DRUG;

ACUTE INFLAMMATORY DEMYELINATING POLYNEUROPATHY; ACUTE MOTOR AXONAL NEUROPATHY; ANTIBODY RESPONSE; ANTIGEN ANTIBODY COMPLEX; ANTIGEN ANTIBODY REACTION; ATAXIA; AUTOIMMUNE DISEASE; BACTERIAL STRAIN; CAMPYLOBACTER ENTERITIS; CAMPYLOBACTER JEJUNI; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CYTOMEGALOVIRUS INFECTION; DEMYELINATING DISEASE; DIAPHRAGM PARALYSIS; FAMILIAL INCIDENCE; GUILLAIN BARRE SYNDROME; HAEMOPHILUS INFECTION; HAEMOPHILUS INFLUENZAE; HOST PATHOGEN INTERACTION; HOST SUSCEPTIBILITY; HUMAN; INFECTION RISK; MOLECULAR MIMICRY; NEUROPATHY; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PERIPHERAL NERVOUS SYSTEM; PHARYNGEAL CERVICAL BRACHIAL NEUROPATHY; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

ANIMALS; ANTIGEN-ANTIBODY REACTIONS; AUTOANTIBODIES; GANGLIOSIDES; GUILLAIN-BARRE SYNDROME; HUMANS; LIPOPOLYSACCHARIDES; MOLECULAR MIMICRY;

BACTERIA (MICROORGANISMS); CAMPYLOBACTER JEJUNI; CYTOMEGALOVIRUS; HAEMOPHILUS INFLUENZAE;

EID: 66249125014     PISSN: 09596658     EISSN: 14602423     Source Type: Journal    
DOI: 10.1093/glycob/cwp027     Document Type: Review

References (216)

1. Akyildiz B, Gumus H, Kumandas S, Coskun A, Baykan A, Yikilmaz A, Kara I, Okur A. 2008. Guillain-Barré syndrome associated with Legionnella infection. J Trop Pediatr. 54(4):275-277.
2. Ang CW, Laman JD, Willison HJ, Wagner ER, Endtz HP, De Klerk MA, Tio-Gillen AP, Van Den Braak N, Jacobs BC, Van Doorn PA. 2002. Structure of Campylobacter jejuni lipopolysaccharides determines antiganglioside specificity and clinical features of Guillain-Barré and Miller Fisher patients. Infect Immun. 70(3):1202-1208.
3. Ang CW, Yuki N, Jacobs BC, Koga M, Van Doorn PA, Schmitz PI, Van Der Meche FG. 1999. Rapidly progressive, predominantly motor Guillain-Barré syndrome with anti-GalNAc-GD1a antibodies. Neurology. 53(9):2122-2127.
4. Ariga T, Miyatake T, Yu RK. 2001. Recent studies on the roles of antiglycosphingolipids in the pathogenesis of neurological disorders. J Neurosci Res. 65(5):363-370.
5. Ariga T, Yu RK. 2005. Antiglycolipid antibodies in Guillain-Barré syndrome and related diseases: Review of clinical features and antibody specificities. J Neurosci Res. 80(1):1-17.
6. Aureli A, Fontecchio G, Altobelli E, Azzarone R, Del Beato T, Fioroni MA, Caporale CM, Adorno D, Papola F. 2007. CD1a and CD1e allele frequencies in an Italian population from the Abruzzo region. Int J Immunopathol Pharmacol. 20(2):415-419.
7. Baravelli M, Fantoni C, Rossi A, Cattaneo P, Anza C. 2008. Guillain-Barré syndrome as a neurological complication of infective endocarditis. Is it really so rare and how often do we recognise it? Int J Cardiol. in press.
8. Bar-Joseph G, Etzioni A, Hemli J, Gershoni-Baruch R. 1991. Guillain-Barré syndrome in three siblings less than 2 years old. Arch Dis Child. 66(9):1078-1079.
9. Brooke JS, Valvano MA. 1996. Molecular cloning of the Haemophilus influenzae gmhA (lpcA) gene encoding a phosphoheptose isomerase required for lipooligosaccharide biosynthesis. J Bacteriol. 178(11):3339-3341.
10. Buchwald B, Zhang G, Vogt-Eisele AK, Zhang W, Ahangari R, Griffin JW, Hatt H, Toyka KV, Sheikh KA. 2007. Anti-ganglioside antibodies alter presynaptic release and calcium influx. Neurobiol Dis. 28(1):113-121.
11. Bullens RW, Halstead SK, O'Hanlon GM, Veitch J, Molenaar PC, Willison HJ, Plomp JJ. 2005. Concanavalin A inhibits pathophysiological effects of antiganglioside GQ1b antibodies at the mouse neuromuscular synapse. Muscle Nerve. 31(6):751-760.
12. Bullens RW, O'Hanlon GM, Wagner E, Molenaar PC, Furukawa K, Furukawa K, Plomp JJ, Willison HJ. 2002. Complex gangliosides at the neuromuscular junction are membrane receptors for autoantibodies and botulinum neurotoxin but redundant for normal synaptic function. J Neurosci. 22(16):6876-6884.
13. Caporale CM, Papola F, Fioroni MA, Aureli A, Giovannini A, Notturno F, Adorno D, Caporale V, Uncini A. 2006. Susceptibility to Guillain-Barré syndrome is associated to polymorphisms of CD1 genes. J Neuroimmunol. 177(1-2):112-118.
14. Chatzipanagiotou S, Kilidireas K, Trimis G, Nicolaou C, Anagnostouli M, Athanassaki C, Giannoulia A, Legakis N, Youroukos S. 2003. Campylobacter jejuni O:19 serotype-associated Guillain-Barré syndrome in a child: The first case reported from Greece. Clin Microbiol Infect. 9(1):69-72.
15. Chi LJ, Wang HB, Zhang Y, Wang WZ. 2007. Abnormality of circulating CD4(+)CD25(+) regulatory T cell in patients with Guillain-Barré syndrome. J Neuroimmunol. 192(1-2):206-214.
16. Chiba A, Kusunoki S, Kuwata S, Juji T, Shibata Y, Kanazawa I. 1995. HLA and anti-GQ1b IgG antibody in Miller Fisher syndrome and Guillain-Barré syndrome. J Neuroimmunol. 61(1):85-88.
17. Chiba A, Kusunoki S, Obata H, Machinami R, Kanazawa I. 1993. Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barré syndrome: Clinical and immunohistochemical studies. Neurology. 43(10):1911-1917.
18. Chiba A, Kusunoki S, Obata H, Machinami R, Kanazawa I. 1997. Ganglioside composition of the human cranial nerves, with special reference to pathophysiology of Miller Fisher syndrome. Brain Res. 745(1-2):32-36.
19. Chiba A, Kusunoki S, Shimizu T, Kanazawa I. 1992. Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome. Ann Neurol. 31(6):677-679.
20. Chida K, Nomura H, Konno H, Takase S, Itoyama Y. 1999. Recurrent Miller Fisher syndrome: Clinical and laboratory features and HLA antigens. J Neurol Sci. 165(2):139-143.
21. Chiu CP, Watts AG, Lairson LL, Gilbert M, Lim D, Wakarchuk WW, Withers SG, Strynadka NC. 2004. Structural analysis of the sialyltransferase CstII from Campylobacter jejuni in complex with a substrate analog. Nat Struct Mol Biol. 11(2):163-170.
22. Condon EM, Tobin A. 2008. Haemophilus influenzae associated Guillain Barré Syndrome with thrombocytopenic purpura and hyperthermia. Anaesth Intensive Care. 36(5):722-725.
23. Creange A, Belec L, Clair B, Raphael JC, Gherardi RK. 1996. Circulating tumor necrosis factor (TNF)-alpha and soluble TNF-alpha receptors in patients with Guillain-Barré syndrome. J Neuroimmunol. 68(1-2):95-99.
24. Csurhes PA, Sullivan AA, Green K, Pender MP, McCombe PA. 2005. T cell reactivity to P0, P2, PMP-22, and myelin basic protein in patients with Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry. 76(10):1431-1439.
25. D'Alessandro R, Casmiro M, Guarino M. Emilia-Romagna Study Group on Clinical and Epidemiological Problems in Neurology. 1999. Risk factors for Guillain-Barré syndrome: A population-based case-control study. J Neurol. 246(11):1004-1009.
26. Davidson DL, O'Sullivan AF, Morley KD. 1992. HLA antigens in familial Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry. 55(6):508-509.
27. De Angelis MV, Notturno F, Caporale CM, Pace M, Uncini A. 2007. Polymorphisms of CD1 genes in chronic dysimmune neuropathies. J Neuroimmunol. 186(1-2):161-163.
28. De Libero G, Moran AP, Gober HJ, Rossy E, Shamshiev A, Chelnokova O, Mazorra Z, Vendetti S, Sacchi A, Prendergast MM, et al. 2005. Bacterial infections promote T cell recognition of self-glycolipids. Immunity 22(6):763-772.
29. De Wals P, Deceuninck G, Boucher RM, Ouakki M. 2008. Risk of Guillain-Barré syndrome following serogroup C meningococcal conjugate vaccine in Quebec, Canada. Clin Infect Dis. 46(8): e75-e77.
30. Deng H, Yang X, Jin T, Wu J, Hu LS, Chang M, Sun XJ, Adem A, Winblad B, Zhu J. 2008. The role of IL-12 and TNF-alpha in AIDP and AMAN. Eur J Neurol. 15(10):1100-1105.
31. Enders U, Karch H, Toyka KV, Michels M, Zielasek J, Pette M, Heesemann J, Hartung HP. 1993. The spectrum of immune responses to Campylobacter jejuni and glycoconjugates in Guillain-Barré syndrome and in other neuroimmunological disorders. Ann Neurol. 34(2):136-144.
32. Figueiredo CA, Klautau GB, Afonso AM, Castrignano SB, Oliveira MI, Curti SP, Squarcina GG, Narimatsu K, Rasslan Z, Lima CA, et al. 2008. Isolation and genotype analysis of rubella virus from a case of Guillain-Barré syndrome. J Clin Virol. 43(3):343-345.
33. Fisher M. 1956. An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia). N Engl J Med. 255(2):57-65.
34. Fry BN, Feng S, Chen YY, Newell DG, Coloe PJ, Korolik V. 2000. The galE gene of Campylobacter jejuni is involved in lipopolysaccharide synthesis and virulence. Infect Immun. 68(5):2594-2601.
35. Fry BN, Korolik V, ten Brinke JA, Pennings MT, Zalm R, Teunis BJ, Coloe PJ, Van Der Zeijst BA. 1998. The lipopolysaccharide biosynthesis locus of Campylobacter jejuni 81116. Microbiology. 144(Pt 8):2049-2061.
36. Geleijns K, Brouwer BA, Jacobs BC, Houwing-Duistermaat JJ, van Duijn CM, van Doorn PA. 2004. The occurrence of Guillain-Barré syndrome within families. Neurology. 63(9):1747-1750.
37. Geleijns K, Emonts M, Laman JD, van Rijs W, van Doorn PA, Hermans PW, Jacobs BC. 2007. Genetic polymorphisms of macrophage-mediators in Guillain-Barré syndrome. J Neuroimmunol. 190(1-2):127-130.
38. Geleijns K, Jacobs BC, Van Rijs W, Tio-Gillen AP, Laman JD, van Doorn PA. 2004. Functional polymorphisms in LPS receptors CD14 and TLR4 are not associated with disease susceptibility or Campylobacter jejuni infection in Guillain-Barré patients. J Neuroimmunol. 150(1-2):132-138.
39. Geleijns K, Laman JD, van Rijs W, Tio-Gillen AP, Hintzen RQ, van Doorn PA, Jacobs BC. 2005. Fas polymorphisms are associated with the presence of anti-ganglioside antibodies in Guillain-Barre syndrome. J Neuroimmunol. 161(1-2):183-189.
40. Geleijns K, Schreuder GM, Jacobs BC, Sintnicolaas K, van Koningsveld R, Meulstee J, Laman JD, van Doorn PA. 2005. HLA class II alleles are not a general susceptibility factor in Guillain-Barré syndrome. Neurology. 64(1):44-49.
41. Gilbert M, Brisson JR, Karwaski MF, Michniewicz J, Cunningham AM, Wu Y, Young NM, Wakarchuk WW. 2000. Biosynthesis of ganglioside mimics in Campylobacter jejuni OH4384. Identification of the glycosyl-transferase genes, enzymatic synthesis of model compounds, and characterization of nanomole amounts by 600-mhz (1)h and (13)c NMR analysis. J Biol Chem. 275(6):3896-3906.
42. Gilbert M, Karwaski MF, Bernatchez S, Young NM, Taboada E, Michniewicz J, Cunningham AM, Wakarchuk WW. 2002. The genetic bases for the variation in the lipo-oligosaccharide of the mucosal pathogen, Campylobacter jejuni. Biosynthesis of sialylated ganglioside mimics in the core oligosaccharide. J Biol Chem. 277(1):327-337.
43. Godschalk PC, Bergman MP, Gorkink RF, Simons G, Van Den Braak N, Lastovica AJ, Endtz HP, Verbrugh HA, van Belkum A. 2006. Identification of DNA sequence variation in Campylobacter jejuni strains associated with the Guillain-Barré syndrome by high-throughput AFLP analysis. BMC Microbiol. 6:32.
44. Godschalk PC, Heikema AP, Gilbert M, Komagamine T, Ang CW, Glerum J, Brochu D, Li J, Yuki N, Jacobs BC, et al. 2004. The crucial role of Campylobacter jejuni genes in anti-ganglioside antibody induction in Guillain-Barré syndrome. J Clin Invest. 114(11): 1659-1665.
45. Godschalk PC, Kuijf ML, Li J, St Michael F, Ang CW, Jacobs BC, Karwaski MF, Brochu D, Moterassed A, Endtz HP, et al. 2007. Structural characterization of Campylobacter jejuni lipooligosaccharide outer cores associated with Guillain-Barré and Miller Fisher syndromes. Infect Immun. 75(3):1245-1254.
46. Gong Y, Tagawa Y, Lunn MP, Laroy W, Heffer-Lauc M, Li CY, Griffin JW, Schnaar RL, Sheikh KA. 2002. Localization of major gangliosides in the PNS: Implications for immune neuropathies. Brain. 125(Pt 11):2491-2506.
47. Goodfellow JA, Bowes T, Sheikh K, Odaka M, Halstead SK, Humphreys PD, Wagner ER, Yuki N, Furukawa K, Furukawa K, et al. 2005. Overexpression of GD1a ganglioside sensitizes motor nerve terminals to anti-GD1a antibody-mediated injury in a model of acute motor axonal neuropathy. J Neurosci. 25(7):1620-1628.
48. Goodyear CS, O'Hanlon GM, Plomp JJ, Wagner ER, Morrison I, Veitch J, Cochrane L, Bullens RW, Molenaar PC, Conner J, et al. 1999. Monoclonal antibodies raised against Guillain-Barré syndrome-associated Campylobacter jejuni lipopolysaccharides react with neuronal gangliosides and paralyze muscle-nerve preparations. J Clin Invest 104(6):697-708.
49. Gorodezky C, Varela B, Castro-Escobar LE, Chavez-Negrete A, Escobar-Gutierrez A, Martinez-Mata J. 1983. HLA-DR antigens in Mexican patients with Guillain-Barré syndrome. J Neuroimmunol. 4(1):1-7.
50. Gregson NA, Jones D, Thomas PK,Willison HJ. 1991. Acute motor neuropathy with antibodies to GM1 ganglioside. J Neurol. 238(8):447-451.
51. Griffin JW, Li CY, Ho TW, Tian M, Gao CY, Xue P, Mishu B, Cornblath DR, Macko C, McKhann GM, et al. 1996. Pathology of themotor-sensory axonal Guillain-Barré syndrome. Ann Neurol. 39(1):17-28.
52. Griffin JW, LiCY, Macko C, Ho TW, Hsieh ST, Xue P, Wang FA, Cornblath DR, McKhann GM, Asbury AK. 1996. Early nodal changes in the acute motor axonal neuropathy pattern of the Guillain-Barré syndrome. J Neurocytol. 25(1):33-51.
53. Guerry P, Ewing CP, Hickey TE, Prendergast MM, Moran AP. 2000. Sialylation of lipooligosaccharide cores affects immunogenicity and serum resistance of Campylobacter jejuni. Infect Immun. 68(12):6656-6662.
54. Hadden RD, Karch H, Hartung HP, Zielasek J, Weissbrich B, Schubert J, Weishaupt A, Cornblath DR, Swan AV, Hughes RA, et al. 2001. Preceding infections, immune factors, and outcome in Guillain-Barré syndrome. Neurology. 56(6):758-765.
55. Hadden RDM, Cornblath DR,Hughes RAC, Zielasek J, Hartung HP, Toyka KV, Swan AV. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. 1998. Electrophysiological classification of Guillain-Barré syndrome: Clinical associations and outcome. Ann Neurol. 44:780-788.
56. Hafer-Macko C, Hsieh ST, Li CY, Ho TW, Sheikh K, Cornblath DR,McKhann GM, Asbury AK, Griffin JW. 1996. Acute motor axonal neuropathy: An antibody-mediated attack on axolemma. Ann Neurol. 40(4):635-644.
57. Hakomori S. 2002. Glycosylation defining cancer malignancy: New wine in an old bottle. Proc Natl Acad Sci USA. 99(16):10231-10233.
58. Halstead SK, Morrison I, O'Hanlon GM, Humphreys PD, Goodfellow JA, Plomp JJ, Willison HJ. 2005. Anti-disialosyl antibodies mediate selective neuronal or Schwann cell injury at mouse neuromuscular junctions. Glia. 52(3):177-189.
59. Halstead SK, O'Hanlon GM, Halstead SK, Humphreys PD, Goodfellow JA, Wagner ER, Smith RA, Willison HJ. 2005. Complement inhibition abrogates nerve terminal injury inMiller Fisher syndrome. Ann Neurol 58(2):203-210.
60. Halstead SK, O'Hanlon GM, Humphreys PD, Morrison DB, Morgan BP, Todd AJ, Plomp JJ,Willison HJ. 2004. Anti-disialoside antibodies kill perisynaptic Schwann cells and damage motor nerve terminals via membrane attack complex in a murine model of neuropathy. Brain 127(Pt 9):2109-2123.
61. Halstead SK, Zitman FM, Humphreys PD, Greenshields K, Verschuuren JJ, Jacobs BC, Rother RP, Plomp JJ, Willison HJ. 2008. Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model. Brain. 131(5):1197-1208.
62. Hao Q, Saida T, Yoshino H, Kuroki S, Nukina M, Saida K. 1999. Anti-GalNAc-GD1a antibody-associated Guillain-Barré syndrome with a predominantly distal weakness without cranial nerve impairment and sensory disturbance. Ann Neurol. 45(6):758-768.
63. + cells in peripheral blood of Guillain-Barré syndrome patients compared to controls. J Clin Neurosci. 15(9):1031-1035.
64. Hartung HP, Toyka KV. 1990. T-cell and macrophage activation in experimental autoimmune neuritis and Guillain-Barré syndrome. Ann Neurol. 27(Suppl):S57-S63.
65. Hillert J, Osterman PO, Olerup O. 1991. No association with HLA-DR, -DQ or -DP alleles in Guillain-Barré syndrome. J Neuroimmunol. 31(1):67-72.
66. Ho TW, Li CY, Cornblath DR, Gao CY, Asbury AK, Griffin JW, McKhann GM. 1997. Patterns of recovery in the Guillain-Barré syndromes. Neurology. 48(3):695-700.
67. Ho TW, Mishu B, Li CY, Gao CY, Cornblath DR, Griffin JW, Asbury AK, Blaser MJ, McKhann GM. 1995. Guillain-Barré syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain. 118(Pt 3):597-605.
68. Ho TW, Willison HJ, Nachamkin I, Li CY, Veitch J, Ung H,Wang GR, Liu RC, Cornblath DR, Asbury AK, et al. 1999. Anti-GD1a antibody is associated with axonal but not demyelinating forms of Guillain-Barré syndrome. Ann Neurol. 45(2):168-173.
69. Houliston RS, Endtz HP, Yuki N, Li J, Jarrell HC, Koga M, van Belkum A, Karwaski MF, Wakarchuk WW, Gilbert M. 2006. Identification of a sialate O-acetyltransferase from Campylobacter jejuni: Demonstration of direct transfer to the C-9 position of terminalalpha-2, 8-linked sialic acid. J Biol Chem. 281(17):11480-11486.
70. Ilyas AA, Cook SD, Mithen FA, Taki T, Kasama T, Handa S, Hamasaki H, Singhal BS, Li SC, Li YT. 1998. Antibodies to GT1a ganglioside in patients with Guillain-Barré syndrome. J Neuroimmunol. 82(2):160-167.
71. Ilyas AA, Li SC, Chou DK, Li YT, Jungalwala FB, Dalakas MC, Quarles RH. 1988. Gangliosides GM2, IV4GalNAcGM1b, and IV4GalNAcGC1a as antigens for monoclonal immunoglobulin M in neuropathy associated with gammopathy. J Biol Chem. 263(9):4369-4373.
72. Jacobs BC, van Doorn PA, Schmitz PI, Tio-Gillen AP, Herbrink P, Visser LH, Hooijkass H, Van Der Meche FG. 1996. Campylobacter jejuni infections and anti-GM1 antibodies in Guillain-Barré syndrome. Ann Neurol. 40(2):181-187.
73. Kaida K, Kamakura K, Ogawa G, Ueda M, Motoyoshi K, Arita M, Kusunoki S. 2008. GD1b-specific antibody induces ataxia in Guillain-Barré syndrome. Neurology. 71(3):196-201.
74. Kaida K, Kanzaki M, Morita D, Kamakura K, Motoyoshi K, Hirakawa M, Kusunoki S. 2006. Anti-ganglioside complex antibodies in Miller Fisher syndrome. J Neurol Neurosurg Psychiatry. 77(9):1043-1046.
75. Kaida K, Kusunoki S, Kamakura K, Motoyoshi K, Kanazawa I. 2000. Guillain-Barre syndrome with antibody to a ganglioside, N acetylgalactosaminyl GD1a. Brain. 123(Pt 1):116-124.
76. Kaida K, Kusunoki S, Kamakura K, Motoyoshi K, Kanazawa I. 2001. Guillain-Barré syndrome with IgM antibody to the ganglioside GalNAc-GD1a. J Neuroimmunol. 113(2):260-267.
77. Kaida K, Kusunoki S, Kamakura K, Motoyoshi K, Kanazawa I. 2003. GalNAc-GD1a in human peripheral nerve: Target sites of anti-ganglioside antibody. Neurology. 61(4):465-470.
78. Kaida K, Morita D, Kanzaki M, Kamakura K, Motoyoshi K, Hirakawa M, Kusunoki S. 2004. Ganglioside complexes as new target antigens in Guillain-Barré syndrome. Ann Neurol. 56(4):567-571.
79. Kaida K, Morita D, Kanzaki M, Kamakura K, Motoyoshi K, Hirakawa M, Kusunoki S. 2007. Anti-ganglioside complex antibodies associated with severe disability in GBS. J Neuroimmunol. 182(1-2):212-218.
80. Kaida K, Sonoo M, Ogawa G, Kamakura K, Ueda-Sada M, Arita M, Motoyoshi K, Kusunoki S. 2008. GM1/GalNAc-GD1a complex:ATarget for pure motor Guillain-Barré syndrome. Neurology. 71(21):1683-1690.
81. Kanipes MI, Papp-Szabo E, Guerry P, Monteiro MA. 2006. Mutation of waaC, encoding heptosyltransferase I in Campylobacter jejuni 81-176, affects the structure of both lipooligosaccharide and capsular carbohydrate. J Bacteriol. 188(9):3273-3279.
82. Kanzaki M, Kaida KI, Ueda M, Morita D, Hirakawa M, Motoyoshi K, Kamakura K, Kusunoki S. 2008. Ganglioside complexes containing GQ1b as targets in Miller Fisher and Guillain-Barré syndromes. J Neurol Neurosurg Psychiatry. 79(10):1148-1152.
83. Kashihara K, Shiro Y, Koga M, Yuki N. 1998. IgG anti-GT1a antibodies which do not cross react with GQ1b ganglioside in a pharyngeal-cervical-brachial variant of Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry. 65(5):799.
84. Khalili-Shirazi A, Gregson NA, Londei M, Summers L, Hughes RA. 1998. The distribution of CD1 molecules in inflammatory neuropathy. J Neurol Sci. 158(2):154-163.
85. Kieseier BC, Clements JM, Pischel HB, Wells GM, Miller K, Gearing AJ, Hartung HP. 1998. Matrix metalloproteinases MMP-9 and MMP-7 are expressed in experimental autoimmune neuritis and the Guillain-Barré syndrome. Ann Neurol. 43(4):427-434.
86. Klena JD, Gray SA, Konkel ME. 1998. Cloning, sequencing, and characterization of the lipopolysaccharide biosynthetic enzyme heptosyltransferase I gene (waaC) from Campylobacter jejuni and Campylobacter coli. Gene. 222(2):177-185.
87. Koga M, GilbertM, Li J, Koike S, Takahashi M, Furukawa K, Hirata K, Yuki N. 2005. Antecedent infections in Fisher syndrome: A common pathogenesis of molecular mimicry. Neurology. 64(9):1605-1611.
88. Koga M, Gilbert M, Takahashi M, Li J, Koike S, Hirata K, Yuki N. 2006. Comprehensive analysis of bacterial risk factors for the development of Guillain-Barré syndrome after Campylobacter jejuni enteritis. J Infect Dis. 193(4):547-555.
89. Koga M, Takahashi M, Masuda M, Hirata K, Yuki N. 2005. Campylobacter gene polymorphism as a determinant of clinical features of Guillain-Barré syndrome. Neurology. 65(9):1376-1381.
90. Koga M, Yoshino H, Morimatsu M, Yuki N. 2002. Anti-GT1a IgG in Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry. 72:767-771.
91. Koga M, Yuki N, Ariga T, Morimatsu M, Hirata K. 1998. Is IgG anti-GT1a antibody associated with pharyngeal-cervical-brachial weakness or oropharyngeal palsy in Guillain-Barré syndrome? J Neuroimmunol. 86(1):74-79.
92. Koga M, Yuki N, Kashiwase K, Tadokoro K, Juji T, Hirata K. 1998. Guillain-Barre and Fisher's syndromes subsequent to Campylobacter jejuni enteritis are associated with HLA-B54 and Cw1 independent of antiganglioside antibodies. J Neuroimmunol. 88(1-2):62-66.
93. Koga M, Yuki N, Tsukada Y, Hirata K, Matsumoto Y. 2003. CDR3 spectratyping analysis of the T cell receptor repertoire in Guillain-Barré and Fisher syndromes. J Neuroimmunol. 141(1-2):112-117.
94. Komagamine T, Yuki N. 2006. Ganglioside mimicry as a cause of Guillain-Barré syndrome. CNS Neurol Disord Drug Targets. 5(4):391-400.
95. Kuijf ML, Geleijns K, Ennaji N, van Rijs W, van Doorn PA, Jacobs BC. 2008. Susceptibility to Guillain-Barré syndrome is not associated with CD1A and CD1E gene polymorphisms. J Neuroimmunol. 205(1-2):110-112.
96. Kuijf ML, Godschalk PC, Gilbert M, Endtz HP, Tio-Gillen AP, Ang CW, van Doorn PA, Jacobs BC. 2007. Origin of ganglioside complex antibodies in Guillain-Barré syndrome. J Neuroimmunol. 188(1-2):69-73.
97. Kusunoki S. 2000. Antiglycolipid antibodies in Guillain-Barré syndrome and autoimmune neuropathies. Am J Med Sci. 319(4):234-239.
98. Kusunoki S, Chiba A, Kanazawa I. 1999. Anti-GQ1b IgG antibody is associated with ataxia as well as ophthalmoplegia. Muscle Nerve. 22(8):1071-1074.
99. Kusunoki S, Chiba A, Kon K, Ando S, Arisawa K, Tate A, Kanazawa I. 1994. N-Acetylgalactosaminyl GD1a is a target molecule for serum antibody in Guillain-Barré syndrome. Ann Neurol. 35(5):570-576.
100. Kusunoki S, Chiba A, Tai T, Kanazawa I. 1993. Localization of GM1 and GD1b antigens in the human peripheral nervous system. Muscle Nerve 16(7):752-756.
101. Kusunoki S, Hitoshi S, Kaida K, Arita M, Kanazawa I. 1999. Monospecific anti-GD1b IgG is required to induce rabbit ataxic neuropathy. Ann Neurol. 45:400-403.
102. Kusunoki S, Iwamori M, Chiba A, Hitoshi S, Arita M, Kanazawa I. 1996. GM1b is a new member of antigen for serum antibody in Guillain-Barré syndrome. Neurology. 47(1):237-242.
103. Kusunoki S, Mashiko H, Mochizuki N, Chiba A, Arita M, Hitoshi S, Kanazawa I. 1997. Binding of antibodies against GM1 and GD1b in human peripheral nerve. Muscle Nerve. 20(7):840-845.
104. Kusunoki S, Shimizu J, Chiba A, Ugawa Y, Hitoshi S, Kanazawa I. 1996. Experimental sensory neuropathy induced by sensitization with ganglioside GD1b. Ann Neurol. 39(4):424-431.
105. Kuwabara S, Misawa S, Takahashi H, Sawai S, Kanai K, Nakata M, Mori M, Hattori T, Yuki N. 2007. Anti-GQ1b antibody does not affect neuromuscular transmission in human limb muscle. J Neuroimmunol. 189(1-2):158-162.
106. Kuwabara S, Yuki N, Koga M, Hattori T, Matsuura D, Miyake M, Noda M. 1998. IgG anti-GM1 antibody is associated with reversible conduction failure and axonal degeneration in Guillain-Barré syndrome. Ann Neurol. 44(2):202-208.
107. Lehmann HC, Lopez PH, Zhang G, Ngyuen T, Zhang J, Kieseier BC, Mori S, Sheikh KA. 2007. Passive immunization with anti-ganglioside antibodies directly inhibits axon regeneration in an animal model. J Neurosci 27(1):27-34.
108. Linton D, Gilbert M, Hitchen PG, Dell A, Morris HR, Wakarchuk WW, Gregson NA, Wren BW. 2000. Phase variation of a beta-1,3 galactosyltransferase involved in generation of the ganglioside GM1-like lipo-oligosaccharide of Campylobacter jejuni. Mol Microbiol. 37(3):501-514.
109. Linton D, Karlyshev AV, Hitchen PG, Morris HR, Dell A, Gregson NA, Wren BW. 2000. Multiple N-acetyl neuraminic acid synthetase (neuB) genes in Campylobacter jejuni: Identification and characterization of the gene involved in sialylation of lipo-oligosaccharide. Mol Microbiol. 35(5):1120-1134.
110. Lopez PH, Zhang G, Bianchet MA, Schnaar RL, Sheikh KA. 2008. Structural requirements of anti-GD1a antibodies determine their target specificity. Brain. 131:1926-1939.
111. Ma JJ, Nishimura M, Mine H, Kuroki S, Nukina M, Ohta M, Saji H, Obayashi H, Saida T, Kawakami H, et al. 1998. HLA and T-cell receptor gene polymorphisms in Guillain-Barré syndrome. Neurology. 51(2):379-384.
112. Magira EE, Papaioakim M, Nachamkin I, Asbury AK, Li CY, Ho TW, Griffin JW, McKhann GM, Monos DS. 2003. Differential distribution of HLA-DQ beta/ DR beta epitopes in the two forms of Guillain-Barré syndrome, acute motor axonal neuropathy and acute inflammatory demyelinating polyneuropathy (AIDP): Identification of DQ beta epitopes associated with susceptibility to and protection from AIDP. J Immunol. 170(6):3074-3080.
113. Martin PT. 2003. Glycobiology of the neuromuscular junction. J Neurocytol. 32(5-8):915-929.
114. McCarthy N, Giesecke J. 2001. Incidence of Guillain-Barré syndrome following infection with Campylobacter jejuni. Am J Epidemiol. 153(6):610-614.
115. McCombe PA, Csurhes PA, Greer JM. 2006. Studies of HLA associations in male and female patients with Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). J Neuroimmunol. 180(1-2):172-177.
116. McKhann GM, Cornblath DR, Griffin JW, Ho TW, Li CY, Jiang Z, Wu G, Zhaori Y, Liu LP, Jou TC, et al. 1993. Acute motor axonal neuropathy: A frequent cause of acute flaccid paralysis in China. Ann Neurol. 33:333-342.
117. Misawa N, Kawashima K, Kondo F, Allos BM, Blaser MJ. 2001. DNA diversity of the wla gene cluster among serotype HS:19 and non-HS:19 Campylobacter jejuni strains. J Endotoxin Res. 7(5):349-358.
118. Miyazaki T, Kusunoki S, Kaida K, Shiina M, Kanazawa I. 2001. Guillain-Barré syndrome associated with IgG monospecific to ganglioside GD1b. Neurology. 56(9):1227-1229.
119. Mizoguchi K, Hase A, Obi T, Matsuoka H, Takatsu M, Nishimura Y, Irie F, Seyama Y, Hirabayashi Y. 1994. Two species of antiganglioside antibodies in a patient with a pharyngeal-cervical-brachial variant of Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry. 57(9):1121-1123.
120. Monos DS, Papaioakim M, Ho TW, Li CY, McKhann GM. 1997. Differential distribution of HLA alleles in two forms of Guillain-Barré syndrome. J Infect Dis. 176(Suppl 2):S180-S182.
121. Munch C, Epplen JT, Meins M, Meyer R, Weber JR, Meyer T. 2008. Severe Guillain-Barré syndrome associated with chromosome 17p11.2-12 duplication. Muscle Nerve. 37(2):256-258.
122. Myhr KM, Vagnes KS, Maroy TH, Aarseth JH, Nyland HI, Vedeler CA. 2003. Interleukin-10 promoter polymorphisms in patients with Guillain-Barré syndrome. J Neuroimmunol. 139(1-2):81-83.
123. Nachamkin I, Allos BM, Ho T. 1998. Campylobacter species and Guillain-Barré syndrome. Clin Microbiol Rev. 11(3):555-567.
124. Nachamkin I, Liu J, Li M, Ung H, Moran AP, Prendergast MM, Sheikh K. 2002. Campylobacter jejuni from patients with Guillain-Barré syndrome preferentially expresses a GD(1a)-like epitope. Infect Immun 70(9):5299-5303.
125. Nachamkin I, Shadomy SV, Moran AP, Cox N, Fitzgerald C, Ung H, Corcoran AT, Iskander JK, Schonberger LB, Chen RT. 2008. Antiganglioside antibody induction by swine (A/NJ/1976/H1N1) and other influenza vaccines: Insights into vaccine-associated Guillain-Barré syndrome. J Infect Dis. 198(2):226-233.
126. Nagashima T, Koga M, Odaka M, Hirata K, Yuki N. 2004. Clinical correlates of serum anti-GT1a IgG antibodies. J Neurol Sci. 219(1-2):139-145.
127. Nagashima T, Koga M, Odaka M, Hirata K, Yuki N. 2007. Continuous spectrum of pharyngeal-cervical-brachial variant of Guillain-Barré syndrome. Arch Neurol. 64(10):1519-1523.
128. 2+channel current is ihhibited by serum from select patients with Guillain-Barré syndrome. Neurochem Res. 34(1):149-157.
129. Nakatani Y, Nagaoka T, Hotta S, Utsunomiya I, Yoshino H, Miyatake T, Hoshi K, Taguchi K. 2007. IgG anti-GalNAc-GD1a antibody inhibits the voltage-dependent calcium channel currents in PC12 pheochromocytoma cells. Exp Neurol. 204(1):380-386.
130. Ogawara K, Kuwabara S, Mori M, Hattori T, Koga M, Yuki N. 2000. Axonal Guillain-Barré syndrome: Relation to anti-ganglioside antibodies and Campylobacter jejuni infection in Japan. Ann Neurol. 48(4):624-631.
131. O'Hanlon GM, Humphreys PD, Goldman RS, Halstead SK, Bullens RW, Plomp JJ, Ushkaryov Y, Willison HJ. 2003. Calpain inhibitors protect against axonal degeneration in a model of anti-ganglioside antibody-mediated motor nerve terminal injury. Brain. 126(Pt 11):2497-2509.
132. O'Hanlon GM, Paterson GJ, Veitch J, Wilson G, Willison HJ. 1998. Mapping immunoreactive epitopes in the human peripheral nervous system using human monoclonal anti-GM1 ganglioside antibodies. Acta Neuropathol 95(6):605-616.
133. O'Hanlon GM, Paterson GJ, Wilson G, Doyle D, McHardie P, Willison HJ. 1996. Anti-GM1 ganglioside antibodies cloned from autoimmune neuropathy patients show diverse binding patterns in the rodent nervous system. J Neuropathol Exp Neurol. 55(2):184-195.
134. O'Hanlon GM, Plomp JJ, Chakrabarti M, Morrison I, Wagner ER, Goodyear CS, Yin X, Trapp BD, Conner J, Molenaar PC, et al. 2001. Anti-GQ1b ganglioside antibodies mediate complement-dependent destruction of the motor nerve terminal. Brain. 124(Pt 5):893-906.
135. Okuda B, Koga M, Katsuta T, Okamoto K, Yuki N. 2002. Fulminant Guillain-Barré syndrome after Campylobacter jejuni enteritis and monospecific anti-GT1a IgG antibody. Intern Med. 41(10):889-891.
136. Oldfield NJ, Moran AP, Millar LA, Prendergast MM, Ketley JM. 2002. Characterization of the Campylobacter jejuni heptosyltransferase II gene, waaF, provides genetic evidence that extracellular polysaccharide is lipid A core independent. J Bacteriol. 184(8):2100-2107.
137. Oldstone MB. 1998. Molecular mimicry and immune-mediated diseases. FASEB J. 12:1255-1265.
138. Pan CL, Yuki N, Koga M, Chiang MC, Hsieh ST. 2001. Acute sensory ataxic neuropathy associated with monospecific anti-GD1b IgG antibody. Neurology. 57(7):1316-1318.
139. Pandey JP, Koga M, Yuki N. 2005. Immunoglobulin KM allotypes are associated with the prevalence of autoantibodies to GD1a ganglioside, but not with susceptibility to the disease, in Japanese patients with Guillain-Barré syndrome. Neurogenetics. 6(4):225-228.
140. Parkhill J, Wren BW, Mungall K, Ketley JM, Churcher C, Basham D, Chillingworth T, Davies RM, Feltwell T, Holroyd S, et al. 2000. The genome sequence of the food-borne pathogen Campylobacter jejuni reveals hypervariable sequences. Nature. 403(6770):665-668.
141. Pegues JC, Chen LS, Gordon AW, Ding L, Coleman WG Jr. 1990. Cloning, expression, and characterization of the Escherichia coli K-12 rfaD gene. J Bacteriol. 172(8):4652-4660.
142. Phongsisay V, Fry BN. 2007. Bidirectional transcription of lipooligosaccharide synthesis genes from Campylobacter jejuni. Int J Med Microbiol. 297(6):431-441.
143. Phongsisay V, Perera VN, Fry BN. 2006. Exchange of lipooligosaccharide synthesis genes creates potential Guillain-Barré syndrome-inducible strains of Campylobacter jejuni. Infect Immun. 74(2):1368-1372.
144. Phongsisay V, Perera VN, Fry BN. 2007. Expression of the htrB gene is essential for responsiveness of Salmonella typhimurium and Campylobacter jejuni to harsh environments. Microbiology. 153(Pt 1):254-262.
145. Phongsisay V, Susuki K, Matsuno K, Yamahashi T, Okamoto S, Funakoshi K, Hirata K, Shinoda M, Yuki N. 2008. Complement inhibitor prevents disruption of sodium channel clusters in a rabbit model of Guillain-Barré syndrome. J Neuroimmunol. 205(1-2):101-104.
146. Plomp JJ, Molenaar PC, O'Hanlon GM, Jacobs BC, Veitch J, Daha MR, van Doorn PA, Van Der Meche FG, Vincent A, Morgan BP, et al. 1999. Miller Fisher anti-GQ1b antibodies: Alpha-latrotoxin-like effects on motor end plates. Ann Neurol. 45(2):189-199.
147. Porcelli SA, Segelke BW, Sugita M, Wilson IA, Brenner MB. 1998. The CD1 family of lipid antigen-presenting molecules. Immunol Today. 19(8):362-368.
148. Press R, Nennesmo I, Kouwenhoven M, Huang YM, Link H, Pashenkov M. 2005. Dendritic cells in the cerebrospinal fluid and peripheral nerves in Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. J Neuroimmunol. 159(1-2):165-176.
149. Press R, Pashenkov M, Jin JP, Link H. 2003. Aberrated levels of cerebrospinal fluid chemokines in Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. J Clin Immunol. 23(4):259-267.
150. + cell populations in Guillain-Barré syndrome. J Neuroimmunol. 183(1-2):232-238.
151. Putzu GA, Figarella-Branger D, Bouvier-Labit C, Liprandi A, Bianco N, Pellissier JF. 2000. Immunohistochemical localization of cytokines, C5b-9 and ICAM-1 in peripheral nerve of Guillain-Barré syndrome. J Neurol Sci. 174(1):16-21.
152. Radhakrishnan VV, Sumi MG, Reuben S, Mathai A, Nair MD. 2003. Circulating tumour necrosis factor alpha & soluble TNF receptors in patients with Guillain-Barré syndrome. Indian J Med Res. 117:216-220.
153. Radhakrishnan VV, Sumi MG, Reuben S, Mathai A, Nair MD. 2004. Serum tumour necrosis factor-alpha and soluble tumour necrosis factor receptors levels in patients with Guillain-Barré syndrome. Acta Neurol Scand. 109(1):71-74.
154. Rees JH, Gregson NA, Hughes RA. 1995. Anti-ganglioside GM1 antibodies in Guillain-Barré syndrome and their relationship to Campylobacter jejuni infection. Ann Neurol. 38(5):809-816.
155. Rees JH, Vaughan RW, Kondeatis E, Hughes RA. 1995. HLA-class II alleles in Guillain-Barré syndrome and Miller Fisher syndrome and their association with preceding Campylobacter jejuni infection. J Neuroimmunol. 62(1):53-57.
156. Reuben S, Sumi MG, Mathai A, Nair MD, Radhakrishnan VV. 2003. Intravenous immunoglobulin reduces serum tumor necrosis factor alpha in patients with Guillain-Barré syndrome. Neurol India. 51(4):487-489.
157. Roberts M, Willison H, Vincent A, Newsom-Davis J. 1994. Serum factor in Miller Fisher variant of Guillain-Barré syndrome and neurotransmitter release. Lancet. 343(8895):454-455.
158. Ropper AH. 1986. Unusual clinical variants and signs in Guillain-Barré syndrome. Arch Neurol. 43(11):1150-1152.
159. Ropper AH, Wijdicks EFM, Truax B. 1991. Guillain-Barré Syndrome Philadelphia, PA: FA Davis. p. 117-118.
160. Saunders M, Rake M. 1965. Familial Guillain-Barré syndrome. Lancet 2(7422):1106-1107.
161. Schmidt-Ott R, Schmidt H, Feldmann S, Brass F, Krone B, Gross U. 2006. Improved serological diagnosis stresses the major role of Campylobacter jejuni in triggering Guillain-Barré syndrome. Clin Vaccine Immunol. 13(7):779-783.
162. Schonberger LB, Hurwitz ES, Katona P, Holman RC, Bregman DJ. 1981. Guillain-Barré syndrome: Its epidemiology and associations with influenza vaccination. Ann Neurol. 9(Suppl):31-38.
163. Sheikh KA, Deerinck TJ, Ellisman MH, Griffin JW. 1999. The distribution of ganglioside-like moieties in peripheral nerves. Brain. 122(Pt 3):449-460.
164. Sheikh KA, Nachamkin I, Ho TW, Willison HJ, Veitch J, Ung H, Nicholson M, Li CY, Wu HS, Shen BQ, et al. 1998. Campylobacter jejuni lipopolysaccharides in Guillain-Barré syndrome: Molecular mimicry and host susceptibility. Neurology. 51(2):371-378.
165. Shu XM, Cai FC, Zhang XP. 2006. Carbohydrate mimicry of Campylobacter jejuni lipooligosaccharide is critical for the induction of anti-GM1 antibody and neuropathy. Muscle Nerve. 33(2):225-231.
166. Sivadon-Tardy V, Orlikowski D, Porcher R, Sharshar T, Durand MC, Enouf V, Rozenberg F, Caudie C, Annane D, Van Der Werf S, et al. 2009. Guillain-Barré syndrome and influenza virus infection. Clin Infect Dis. 48(1):48-56.
167. Stintzi A. 2003. Gene expression profile of Campylobacter jejuni in response to growth temperature variation. J Bacteriol. 185(6):2009-2016.
168. Sugimoto H, Wakata N, Kishi M, Fujioka T, Kurihara T, Irie Y, Saito T. 2002. A case of Guillain-Barré syndrome associated with cerebellar ataxia and positive serum anti-GD1b IgG antibody. J Neurol. 249(3):346-347.
169. Susuki K, Baba H, Tohyama K, Kanai K, Kuwabara S, Hirata K, Furukawa K, Furukawa K, Rasband MN, Yuki N. 2007. Gangliosides contribute to stability of paranodal junctions and ion channel clusters in myelinated nerve fibers. Glia. 55(7):746-757.
170. Susuki K, Nishimoto Y, Yamada M, Baba M, Ueda S, Hirata K, Yuki N. 2003. Acute motor axonal neuropathy rabbit model: Immune attack on nerve root axons. Ann Neurol. 54(3):383-388.
171. Susuki K, Rasband MN, Tohyama K, Koibuchi K, Okamoto S, Funakoshi K, Hirata K, Baba H, Yuki N. 2007. Anti-GM1 antibodies cause complement-mediated disruption of sodium channel clusters in peripheral motor nerve fibers. J Neurosci. 27(15):3956-3967.
172. Svennerhohn L, Månsson JE, Li YT. 1973. Isolation and structural determination of a novel ganglioside, a disialosylpentahexosylceTamide from human brain. J Riol Chen 248(2):740-742.
173. Szymanski CM, Yao R, Ewing CP, Trust TJ,.Guerry P. 1990. Evidence for a system of general protein glycosylation in Campylobacter jejuni. Mol Microbiol. 32(5):1022-1030.
174. Taguchi K, Ren J, Utsunomiya I, Aoyagi H, Fujita N, Ariga T, Miyatake T, Yoshino H. 2004. Neurophysiological and immunohistochemical studies on Guillain-Barré syndrome with IgG anti-GaINAc-GD1a.antibodies-effects on neuromuscular transmission. J Neurol Sci. 225(1-2):91-98.
175. Talwar V, Mehndiratta N, Verma PK. 2007. Barium poisoning mimicking Guillain-Barré syndrome. J Assoc Physicians India. 55:658-660.
176. Thin CC, O'Brien SJ, Petersen I, Islam A, Hayward A, Rodrigues LC. 2007. Guillain-Barré syndrome and preceding infection with campylobacter influenza and Epstein-Barr virus in the general practice research database. PLoS ONE. 2(4):e344.
177. Tsang RS, Valdivieso-Garcia A. 2003. Pathogenesis of Guillain-Barre syndrome. Expert Rev Anti Infect Ther. 1(4):597-608.
178. Usuki S, Thompson SA, Rivner MH, Taguchi K, Ariga T, Tu RK. 2006a. Molecular mimicry: Sensitization of Lewis rats with Campylobacter jejuni llipopolysaccharides induces formation of antibody toward GD3 ganglioside. J Neurosc Res. 83(2):274-284.
179. Usuki S, Taguchi K, Cawthraw SA, Shibata K, Ariga. T, Newell DG, Ya RK. 2006b. Human and chicken antibodies to gangliosides following infection by Campylobacter jejuni. Exp Neurol. 200(1):50-55.
180. Usuki S, Sanchez J, Ariga T, Utsnomiya I, Tanguchi K, Rivner MH, Yu RK. 2005. AJDP and CIDP having specific antibodies to the carbohydrate epitope (NeuAcα2-8 NeuAcα2-3Galβ 1-4Glc-) of gangliosides. J Neurol Sci. 232:37-44.
181. van Belkum A, Van Den Braak N, Godschalk P, Ang W, Jacobs B, Gilbert M, Wakarchuk W, Verbrugh H, Endtz H. 2001. A Campylobacter jejuni gene associated with immune-mediated neuropathy. Nat Med. 7(7):752-753.
182. Van Den Berg LH, Marrink 1, de Jager AE, de Jong HJ, van Imhoff GW, Latov N, Sadiq SA. 1992. Anti-GM1 antibodies in patients with Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry. 55(1):8-11.
183. Van Der Pol WL, Van Den Berg LH, Scheepers RH, Van Der Bom JG, van Doom PA, van Koningsveld R, Van Den Broek MC, Wokke JH, van de Winkel JG. 2000. IgG receptor IIa alleles determine susceptibility and severity of Guillain-Barré syndrome. Neurology. 54(8):1661-1665.
184. Van Rhijn I, Van Den Berg LH, Bosboom WM, Otten HG, Logtenberg T. 2000. Expression of accessory molecules for T-cell activation in peripheral nerve of patients with CIDP and vasculitic neuropathy. Brain. 123(Pt 10):2020-2029.
185. van Sorge NM, Van Der Pol WL, Jansen MD, Geleijns KP, Kalmijn S, Hughes RA, Rees JH, Pritchard J, Vedeler CA, Myhr KM, et al. Z005. Severity of Guillain-Barré syndrome is associated with Fc gamma receptor III polymorphisms. J Neuroimmunol. 162(1-2):157-164.
186. Varki A. 1994. Selectin ligands. Proc Natl Acad Sci USA. 91(16):7390-7397.
187. Vedeler CA, Raknes G, Myhr KM, Nyland H. 2000. IgG Fc-receptor polymorphisms in Guillain-Barré syndrome. Neurology. 55(5):705-707.
188. Visser LH, Van Der Meche FG, Van Doom PA, Meulstee J, Jacobs BC, Oomes PG, Kleyweg RP, Meulstee J. Dutch Guillain-Barré Study Group. 1995. Guillain-Barré syndrome without sepsory loss (acute motor neuropathy). A subgroup with specific clinical, electrodiagnostic and laboratory features. Brain. 118(Pt 4):841-847.
189. Vriesendorp FJ, Triggs WJ, Mayer RF, Koski CL. 1995. Electrophysiological studies in Guillain-Barré syndrome: Correlation with antibodies to GM1, GD1B and Campylobacter jejuni. J Neurol. 242(7):460-465.
190. Wicklein EM, Pfeiffer G, Yuki N, Hartard C, Kunze K. 1997. Prominent sensory ataxia in Guillain-Barré syndrome associated with IgǴ anti-GD1b antibody. J Neurol Sci. 151(2):227-229.
191. Willison HJ. 2005. Ganglioside complexes: New autoantibody targets in Guillain-Barré syndromes. Nat Clin Pract Neurol. 1(1):2-3.
192. Willison HJ, O'Hanlon GM. 1999. The immunopathogenesis of Miller Fisher syndrome. J Neuroimmunol. 100(1-2):3-12.
193. Willison HJ, O'Hanlon GM, Paterson G, Veitch J, Alson G, Roberts M, Tang T, Vincent A. 1996. A somatically mutated human antiganghoside IgM antibody that induces experimental neuropathy in mice is encoded by the variable region heavy chain gene, V1-18. J Clin Invesn 97(5):1155-1164.
194. Willison HJ, Yuki N. 2002. Peripheral neuropathies and anti-glycolipid antibodies. Brain. 125(12):2591-2625.
195. Wuncherpfennig KW. 2001. Mechanisms for the induction of autoimmunity by infectious agents. J Clin Invest. 108(8):1097-1104.
196. Xiang SL, Zhong M, Cai FC, Deng B, Zhang XP. 2006. The sialic acid residue is a crucial component of C. jejuni lipooligosaccharide ganglio-side mimicry in the induction Guillain-Barré syndrome. J Neuroimmunol. 174(1-2):126-132.
197. Yako K, Kusunoki S, Kanazawa I. 1999. Serum antibody against a peripheral nerve myelin ganglioside, LM1, in Guillain-Barré syndrome. J Neurol Sci. 168(2):85-89.
198. Yardimci N, Gulsen S, Avci AY, Altinors N, Zileli T, Can U. 2009. Can subdural hematoma be a trigger for Guillain-Barre syndrome? Int J Neurosci. 119(3):366-372.
199. Yonekura K, Yokota S, Tanaka S, Kubota M, Fujii N, Matsomoto H, Chiba S. 2004. Prevalance of anti-heat shock protein antibodies in cerebrospinal fluids of patient with Guillain-Barré syndrome. J Neuroimmunol. 156 (1-2):204-209.
200. Yoshino H, Utsunomiya I, Taguchi K, Ariga T, Nagaoka T, Aoyagi H, Asano A, Yamada M, Miyatake T. 2005. GalNAc-GD1a is localized specifically in ventral spinal roots, but not in dorsal spinal roots. Brain Res. 1057(1-2):177-180.
201. Yu RK, Bieberich E, Xia T, Zeng G. 2004. Regulation of ganghoside biosynthesis in the nervous system. J Lipid Res. 45(5):783-793.
202. Yu RK, toh T, Yohe HC, Macala LJ. 1983. Characterization of some minor gangliosides in Tay-Sachs brains. Brain Res. 275(1):47-52.
203. Yu RK, Usuki S, Ariga T. 2006. Ganglioside molecular mimicry and its pathological roles in Guillain-Barre syndrome and related diseases. Infect Immun. 74(12):6517-6527.
204. Yuki N. 2000. Current cases in which epitope mimicry is considered a component cause of autoimmune disease: Guillain-Barré syndrome. Cell Mol Life Sci. 57(4):527-533.
205. Yuki N. 2007a. Ganglioside mimicry and peripheral nerve disease. Muscle Nerve. 35(6):691-711.
206. Yuki N. 2007b. Campylobacter sialyltransferase gene polymorphism directs clinical features of Gufflain-Barré syndrome. J Neurochem 103(Suppl 1):150-158.
207. Yuki N, Ang CW, Koga M, Jacobs BC, van Doom PA, Hirata K, Van Der Meche FG. 2000. Clinical features and response to treatment in Guillain-Barré syndrome associated with antibodies to GM1b ganghoside. Ann Neurol. 47(3):314-321.
208. Yuki N, Hirata K. 1998. Fisher's syndrome and group A streptococcal infection. J Neurol Sci. 160(1):64-.66.
209. Yuki N, Sato S, Itoh T, Miyatake T. 1991. HLA-B35 and acute axonal polyneuropathy following Campylobacter infection. Neurology. 41(10):1561-1563.
210. Yuki N, Susuki K, Hirata K. 2000a. Ataxic Guillain-Barré syndrome with anti-GQ1b antibody: Relation to Miller Fisher syndrome. Neurology. 54(9):1851-1853.
211. Yuki N, Susuki K, Hirata K. 2000b. Ataxic form of Guillain-Barré syndrome associated with anti-GD1b IgG antibody. J Neural Neurosurg Psychiatry. 69(1):136-137.
212. Yuki N, Susuki K, Koga M, Nishimoto Y, Odaka M, Hirata K, Taguchi K, Miyatake T, Furukawa K, Kobata T, et al. 2004. Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide, causes Guillain-Barré syndrome. Proc Notl Acad Sci USA. 101(31):11404-11409.
213. Yaki N, Tsujino Y. 1995. Familial Gufflain - Barré syndrome subsequent to Campylobacter jejuni enteritis. J Pediatr. 126(1):162.
214. Yuki N, Yamada M, Koga M, Odaka M, Susuki K, Tagawa Y, Ueda S, Kasama T, Ohnishi A, Hayashi S, et al. 2001. Animal model of axonal Guillain-Barré syndrome induced by sensitization with GM1 ganglioside. Ann Neurol. 49(6):712-720.
215. Zhang J, Dong H, Li B, Li CY, Guo L. 2007. Association of turnor necrosis factor polymorphisms with Guillain-Barré syndrome. Eur Neurol. 58(1):21-25.
216. Zhang L, Arrington S, Keung YK. 2008. Guillain-Barrésyndrome after transplantation. Leuk Lymphoma. 49(2):291-297.